Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

FDA Approves Firvanq for C.diff-associated Diarrhea

CutisPharma news release; 2018 Jan 29

The FDA has approved Firvanq (vancomycin hydrochloride) oral liquid therapy to treat Clostridium difficile-associated diarrhea and enterocolitis resulting from Staphylococcus aureus.

Indications: Firvanq (vancomycin hydrochloride) for oral solution, is approved for the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains.

Dosage/administration: Firvanq will be available in 25 mg/mL and 50 mg/mL strengths in convenient 150 mL and 300 mL sizes. It is designed to be easy to use and has the potential to be a cost-effective alternative to existing vancomycin therapies.

Citation:

CutisPharma announces FDA approval of FIRVANQ. [news release]. Wilmington, MA: CutisPharma; January 29, 2018. http://cutispharma.com/cutispharma-announces-fda-approval-firvanq/. Accessed January 30, 2018.

Must Reads in Antimicrobial-resistant infections

Antibiotic Use and Hospital Onset CDI Infection, Clin Infect Dis; ePub 2019 Mar 1; Kazakova, et al

Patient Follow-Up in OPAT & Readmissions, Clin Infect Dis; ePub 2019 Feb 27; Palms, et al

Decolonization Lowers Postdischarge Infection Risk, N Engl J Med; 2019 Feb 14; Huang, et al

Antibiotic Stewardship & Fluoroquinolone Prescribing, Clin Infect Dis; ePub 2019 Feb 13; Vaughn, et al

30-Day Readmission After S. aureus Bacteremia, Clin Infect Dis; ePub 2019 Feb 11; Inagaki, et al